Ocular to price IPO of 5 million shares between $14.00 and $16.00

Morgan Stanley, Cowen, RBC to be the bookrunners; Oppenheimer assists

By Devika Patel

Knoxville, Tenn., July 11 – Ocular Therapeutix, Inc. will sell 5 million common shares in its initial public offering with a greenshoe option of 750,000 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The deal was announced on June 20.

The shares will be sold at a price expected to fall between $14.00 and $16.00 per share.

Morgan Stanley, Cowen and Co. and RBC Capital Markets are the joint bookrunning managers. Oppenheimer & Co. is the co-manager.

Proceeds will be used for clinical trials, research and development, sales and marketing, expanding manufacturing capacity, working capital and other general corporate purposes.

The biopharmaceutical company is based in Bedford, Mass. The company intends to list its common stock on the Nasdaq under the symbol “OCUL.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.